Literature DB >> 24443998

Epigenetic mechanisms in the pathogenesis of Lynch syndrome.

P Peltomäki1.   

Abstract

Inherited defects in the DNA mismatch repair (MMR) system, MLH1, MSH2, MSH6, and PMS2 genes, underlie Lynch syndrome, one of the most prevalent cancer syndromes in man. The syndrome offers a model for cancers arising through MMR defects and microsatellite instability, which applies to ~ 15% of all colorectal, endometrial, and other cancers. Lynch syndrome also illustrates the significance of the epigenetic component in cancer development. Inactivation of tumor suppressor genes by epigenetic mechanisms is an acquired property of many tumors developing in Lynch syndrome. Furthermore, constitutional epimutations of MMR genes may explain a proportion of mutation-negative families lacking MLH1 or MSH2 protein expression in tumor tissue. This review provides an update of the molecular basis of Lynch syndrome by focusing on the role of epigenetic mechanisms in the pathogenesis of the disease.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DNA mismatch repair genes; EPCAM; Lynch syndrome; MLH1; MSH2; epimutation; methylation; microsatellite instability; mutation

Mesh:

Substances:

Year:  2014        PMID: 24443998     DOI: 10.1111/cge.12349

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  18 in total

1.  EGFR inhibits DNA mismatch repair.

Authors:  Peggy Hsieh; Alexander H Pearlman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

2.  Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome.

Authors:  Trilokesh D Kidambi; Amie Blanco; Jessica Van Ziffle; Jonathan P Terdiman
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

Review 3.  The evolution of colorectal cancer genetics-Part 1: from discovery to practice.

Authors:  Andrew T Schlussel; Ronald A Gagliano; Susan Seto-Donlon; Faye Eggerding; Timothy Donlon; Jeffrey Berenberg; Henry T Lynch
Journal:  J Gastrointest Oncol       Date:  2014-10

4.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.

Authors:  Francesca Crucianelli; Rossella Tricarico; Daniela Turchetti; Greta Gorelli; Francesca Gensini; Roberta Sestini; Laura Giunti; Monica Pedroni; Maurizio Ponz de Leon; Serenella Civitelli; Maurizio Genuardi
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

Review 5.  New insights into the mechanism of DNA mismatch repair.

Authors:  Gloria X Reyes; Tobias T Schmidt; Richard D Kolodner; Hans Hombauer
Journal:  Chromosoma       Date:  2015-04-11       Impact factor: 4.316

6.  First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.

Authors:  H Ziada-Bouchaar; K Sifi; T Filali; T Hammada; D Satta; N Abadi
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

7.  MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.

Authors:  Caroline Kientz; Fabienne Prieur; Alix Clemenson; Marie-Odile Joly; Marie-Laure Stachowicz; Jessie Auclair; Valéry Attignon; Renaud Schiappa; Qing Wang
Journal:  Fam Cancer       Date:  2019-11-19       Impact factor: 2.375

Review 8.  Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer.

Authors:  Gulcin Tezcan; Berrin Tunca; Secil Ak; Gulsah Cecener; Unal Egeli
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

9.  Abdominal wall metastasis following open nephroureterectomy for upper tract urothelial carcinoma in a patient with Lynch syndrome.

Authors:  Michael John Stewart; Glen R Guerra; Tom R Sutherland; Sandra L Elmer
Journal:  BMJ Case Rep       Date:  2016-03-31

10.  Mlh1 heterozygosity and promoter methylation associates with microsatellite instability in mouse sperm.

Authors:  Kul S Shrestha; Minna M Tuominen; Liisa Kauppi
Journal:  Mutagenesis       Date:  2021-07-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.